Plasma exosome tRFs marker and application thereof to breast cancer diagnosis

Abstract

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

Description

technical field [0001] The invention relates to the field of breast cancer diagnosis, in particular to a plasma exosome tRFs marker and its application in breast cancer diagnosis. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, and its incidence rate ranks first among female malignant tumors in my country, becoming the "number one killer" that threatens women's health. Early breast cancer is not easy to find, and often sees a doctor only when there are obvious pathological symptoms. Although surgery, radiotherapy, chemotherapy, endocrine therapy, and biological therapy have improved the long-term survival rate of breast cancer patients, the overall survival rate is still not ideal. Therefore, improving the diagnosis and curative effect monitoring of breast cancer is the key to improving the treatment effect and prolonging the survival time. Ideal breast cancer biomarkers should have the characteristics of high specificity, hi...

AI Technical Summary

Problems solved by technology

[0007] (1) Serological tumor markers, such as carbohydrate antigens CA153, CA50, and carcinoembryonic antigen (CEA), have problems such as low sensitivity and poor specificity;

[0008] (2) Although the sensitivity of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) has been greatly improved, their content is affected by the clearance and degradation of blood and lymphatic circulation, resulting in low detection rate, complex sources, and poor specificity. Disadvantages, false positives are prone to occur in other tumors and benign lesions;

[0009] (3) Using IncRNA, cfDNA and mRNA in exosomes as markers, due to the complex regulatory mechanism of IncRNA, the complicated mutations of cfDNA, and the instability of mRNA, the detection of it as a breast tumor marker still cannot replace pathological cells medical examination;

Images